Targeting bromodomains: epigenetic readers of lysine acetylation (original) (raw)

• Holliday, R. The inheritance of epigenetic defects. Science 238, 163–170 (1987).
  CAS PubMed Google Scholar
• Magnaghi-Jaulin, L. et al. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391, 601–605 (1998).
  CAS PubMed Google Scholar
• Sugita, K. et al. MLL-CBP fusion transcript in a therapy-related acute myeloid leukemia with the t(11;16)(q23;p13) which developed in an acute lymphoblastic leukemia patient with Fanconi anemia. Genes Chromosomes Cancer 27, 264–269 (2000).
  CAS PubMed Google Scholar
• Hennekam, R. C. Rubinstein-Taybi syndrome. Eur. J. Hum. Genet. 14, 981–985 (2006).
  CAS PubMed Google Scholar
• Barneda-Zahonero, B. & Parra, M. Histone deacetylases and cancer. Mol. Oncol. 6, 579–589 (2012).
  CAS PubMed PubMed Central Google Scholar
• Lee, J. H., Choy, M. L. & Marks, P. A. Mechanisms of resistance to histone deacetylase inhibitors. Adv. Cancer Res. 116, 39–86 (2012).
  CAS PubMed Google Scholar
• Buurman, R. et al. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology 143, 811–820.e15 (2012).
  CAS PubMed Google Scholar
• Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nature Rev. Drug Discov. 5, 769–784 (2006).
  CAS Google Scholar
• Garber, K. HDAC inhibitors overcome first hurdle. Nature Biotech. 25, 17–19 (2007).
  CAS Google Scholar
• McConkey, D. J., White, M. & Yan, W. HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer. Adv. Cancer Res. 116, 131–163 (2012).
  CAS PubMed Google Scholar
• Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529–533 (2011).
  CAS PubMed PubMed Central Google Scholar
• Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904–917 (2011).
  CAS PubMed PubMed Central Google Scholar
• Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524–528 (2011).
  CAS PubMed PubMed Central Google Scholar
• Nicodeme, E. et al. Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119–1123 (2010).
  CAS PubMed PubMed Central Google Scholar
• Yang, Z. et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 19, 535–545 (2005).
  CAS PubMed Google Scholar
• Bres, V., Yoh, S. M. & Jones, K. A. The multi-tasking P-TEFb complex. Curr. Opin. Cell Biol. 20, 334–340 (2008).
  CAS PubMed PubMed Central Google Scholar
• Marushige, K. Activation of chromatin by acetylation of histone side chains. Proc. Natl Acad. Sci. USA 73, 3937–3941 (1976).
  CAS PubMed PubMed Central Google Scholar
• Shogren-Knaak, M. et al. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 311, 844–847 (2006).
  CAS PubMed Google Scholar
• Celic, I. et al. The sirtuins Hst3 and Hst4p preserve genome integrity by controlling histone H3 lysine 56 deacetylation. Curr. Biol. 16, 1280–1289 (2006).
  CAS PubMed Google Scholar
• Kouzarides, T. Chromatin modifications and their function. Cell 128, 693–705 (2007).
  CAS PubMed Google Scholar
• Jenuwein, T. & Allis, C. D. Translating the histone code. Science 293, 1074–1080 (2001).
  CAS PubMed Google Scholar
• Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834–840 (2009).
  Article CAS PubMed Google Scholar
• Zhao, S. et al. Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000–1004 (2010).
  CAS PubMed PubMed Central Google Scholar
• Kouzarides, T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 19, 1176–1179 (2000).
  CAS PubMed PubMed Central Google Scholar
• Kazantsev, A. G. & Thompson, L. M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nature Rev. Drug Discov. 7, 854–868 (2008).
  CAS Google Scholar
• Thurn, K. T., Thomas, S., Moore, A. & Munster, P. N. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 7, 263–283 (2011).
  CAS PubMed Google Scholar
• Tamkun, J. W. et al. brahma: a regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2. Cell 68, 561–572 (1992).
  CAS PubMed Google Scholar
• Yang, X. J., Ogryzko, V. V., Nishikawa, J., Howard, B. H. & Nakatani, Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382, 319–324 (1996).
  CAS PubMed Google Scholar
• Dhalluin, C. et al. Structure and ligand of a histone acetyltransferase bromodomain. Nature 399, 491–496 (1999).
  CAS PubMed Google Scholar
• Gregory, G. D. et al. Mammalian ASH1L is a histone methyltransferase that occupies the transcribed region of active genes. Mol. Cell. Biol. 27, 8466–8479 (2007).
  CAS PubMed PubMed Central Google Scholar
• Malik, S. & Bhaumik, S. R. Mixed lineage leukemia: histone H3 lysine 4 methyltransferases from yeast to human. FEBS J. 277, 1805–1821 (2010).
  CAS PubMed PubMed Central Google Scholar
• Trotter, K. W. & Archer, T. K. The BRG1 transcriptional coregulator. Nucl. Recept. Signal 6, e004 (2008).
  PubMed PubMed Central Google Scholar
• Cavellan, E., Asp, P., Percipalle, P. & Farrants, A. K. The WSTF-SNF2h chromatin remodeling complex interacts with several nuclear proteins in transcription. J. Biol. Chem. 281, 16264–16271 (2006).
  CAS PubMed Google Scholar
• Venturini, L. et al. TIF1γ, a novel member of the transcriptional intermediary factor 1 family. Oncogene 18, 1209–1217 (1999).
  CAS PubMed Google Scholar
• Jacobson, R. H., Ladurner, A. G., King, D. S. & Tjian, R. Structure and function of a human TAFII250 double bromodomain module. Science 288, 1422–1425 (2000).
  CAS PubMed Google Scholar
• Xue, Y. et al. The human SWI/SNF-B chromatin-remodeling complex is related to yeast Rsc and localizes at kinetochores of mitotic chromosomes. Proc. Natl Acad. Sci. USA 97, 13015–13020 (2000).
  CAS PubMed PubMed Central Google Scholar
• Wu, S. Y. & Chiang, C. M. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J. Biol. Chem. 282, 13141–13145 (2007).
  CAS PubMed Google Scholar
• Muller, S., Filippakopoulos, P. & Knapp, S. Bromodomains as therapeutic targets. Expert Rev. Mol. Med. 13, e29 (2011).
  PubMed PubMed Central Google Scholar
• Prinjha, R. K., Witherington, J. & Lee, K. Place your BETs: the therapeutic potential of bromodomains. Trends Pharmacol. Sci. 33, 146–153 (2012).
  CAS PubMed Google Scholar
• Belkina, A. C. & Denis, G. V. BET domain co-regulators in obesity, inflammation and cancer. Nature Rev. Cancer 12, 465–477 (2012).
  CAS Google Scholar
• Filippakopoulos, P. et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149, 214–231 (2012).
  CAS PubMed PubMed Central Google Scholar
• Owen, D. J. et al. The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase Gcn5p. EMBO J. 19, 6141–6149 (2000).
  CAS PubMed PubMed Central Google Scholar
• Moriniere, J. et al. Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 461, 664–668 (2009).
  CAS PubMed Google Scholar
• Zeng, L. et al. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. J. Am. Chem. Soc. 127, 2376–2377 (2005).
  CAS PubMed Google Scholar
• Sueoka, H., Kobayashi, H., Ehara, S. & Komatsu, H. Thienotriazolodiazepine compounds & medicinal uses thereof. WO 98/11111 A1 (1998).
• Adachi, K. et al. Thienotriazolodiazepine compound and a medicinal use thereof. WO 2006/1 29623 A1 (2006).
• Miyoshi, S., Ooike, S., Iwata, K., Hikawa, H. & Sugaraha, K. Anti tumor agent. WO 2009/084693 (2009).
• Sachchidanand et al. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. Chem. Biol. 13, 81–90 (2006).
• Borah, J. C. et al. A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem. Biol. 18, 531–541 (2011).
  CAS PubMed PubMed Central Google Scholar
• Zhang, G. et al. Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains. J. Med. Chem. 56, 9251–9264 (2013).
  CAS PubMed PubMed Central Google Scholar
• Ito, T. et al. Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors. Chem. Biol. 18, 495–507 (2011).
  CAS PubMed Google Scholar
• Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010).
  CAS PubMed PubMed Central Google Scholar
• Zhang, G. et al. Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J. Biol. Chem. 287, 28840–28851 (2012).
  CAS PubMed PubMed Central Google Scholar
• Devaiah, B. N. et al. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc. Natl Acad. Sci. USA 109, 6927–6932 (2012).
  CAS PubMed PubMed Central Google Scholar
• Chung, C. W. et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J. Med. Chem. 54, 3827–3838 (2011).
  CAS PubMed Google Scholar
• Filippakopoulos, P. et al. Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family. Bioorg. Med. Chem. 20, 1878–1886 (2012).
  CAS PubMed PubMed Central Google Scholar
• Hewings, D. S. et al. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J. Med. Chem. 54, 6761–6770 (2011).
  CAS PubMed PubMed Central Google Scholar
• Hewings, D. S. et al. Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands. J. Med. Chem. 56, 3217–3227 (2013).
  CAS PubMed PubMed Central Google Scholar
• Bamborough, P. et al. Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. J. Med. Chem. 55, 587–596 (2012).
  CAS PubMed Google Scholar
• Gehling, V. S. et al. Discovery, design, and optimization of isoxazole azepine BET inhibitors. ACS Med. Chem. Lett. 4, 835–840 (2013).
  CAS PubMed PubMed Central Google Scholar
• Hay, D. et al. The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains. Medchemcomm 4, 140–144 (2013).
  CAS PubMed Google Scholar
• Mirguet, O. et al. Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem 9, 580–589 (2014).
  CAS PubMed Google Scholar
• Fish, P. V. et al. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J. Med. Chem. 55, 9831–9837 (2012).
  CAS PubMed PubMed Central Google Scholar
• Khmelnitsky, Y. L. et al. In vitro biosynthesis, isolation, and identification of predominant metabolites of 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3_H_)-one (RVX-208). Eur. J. Med. Chem. 64, 121–128 (2013).
  CAS PubMed Google Scholar
• Fedorov, O. et al. [1,2,4]Triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains. J. Med. Chem. 57, 462–476 (2014).
  CAS PubMed Google Scholar
• Ciceri, P. et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nature Chem. Biol. 10, 305–312 (2014).
  CAS Google Scholar
• Lucas, X. et al. 4-acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew. Chem. Int. Ed Engl. 52, 14055–14059 (2013).
  CAS PubMed Google Scholar
• Zhao, L. et al. Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain. J. Med. Chem. 56, 3833–3851 (2013).
  CAS PubMed Google Scholar
• Vidler, L. R. et al. Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening. J. Med. Chem. 56, 8073–8088 (2013).
  CAS PubMed PubMed Central Google Scholar
• Chung, C. W., Dean, A. W., Woolven, J. M. & Bamborough, P. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. J. Med. Chem. 55, 576–586 (2012).
  CAS PubMed Google Scholar
• Ferguson, F. M. et al. Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain. J. Med. Chem. 56, 10183–10187 (2013).
  CAS PubMed PubMed Central Google Scholar
• Vidler, L. R., Brown, N., Knapp, S. & Hoelder, S. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J. Med. Chem. 55, 7346–7359 (2012).
  CAS PubMed PubMed Central Google Scholar
• Zhou, M.-M., Zeng, L. & Wang, Z. Preparation of modulators of histone acetyltransferase bromodomain binding to protein partners for use in treating viral infections by affecting transcription. WO 2006/083692 A2 (2006).
• Sasaki, K., Ito, T., Nishino, N., Khochbin, S. & Yoshida, M. Real-time imaging of histone H4 hyperacetylation in living cells. Proc. Natl Acad. Sci. USA 106, 16257–16262 (2009).
  CAS PubMed PubMed Central Google Scholar
• Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3–26 (2001).
  CAS PubMed Google Scholar
• Olkkola, K. T. & Ahonen, J. Midazolam and other benzodiazepines. Handb Exp. Pharmacol. 182, 335–360 (2008).
  CAS Google Scholar
• Verster, J. C. & Volkerts, E. R. Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. CNS Drug Rev. 10, 45–76 (2004).
  CAS PubMed PubMed Central Google Scholar
• Sofou, K., Kristjansdottir, R., Papachatzakis, N. E., Ahmadzadeh, A. & Uvebrant, P. Management of prolonged seizures and status epilepticus in childhood: a systematic review. J. Child Neurol. 24, 918–926 (2009).
  PubMed Google Scholar
• Quirk, K. et al. [3_H_]L-655,708, a novel ligand selective for the benzodiazepine site of GABAA receptors which contain the alpha 5 subunit. Neuropharmacology 35, 1331–1335 (1996).
  CAS PubMed Google Scholar
• Casula, M. A. et al. Identification of amino acid residues responsible for the α5 subunit binding selectivity of L-655,708, a benzodiazepine binding site ligand at the GABAA receptor. J. Neurochem. 77, 445–451 (2001).
  CAS PubMed Google Scholar
• Atack, J. R. The benzodiazepine binding site of GABAA receptors as a target for the development of novel anxiolytics. Expert Opin. Investig. Drugs 14, 601–618 (2005).
  CAS PubMed Google Scholar
• Korpi, E. R., Mattila, M. J., Wisden, W. & Luddens, H. GABA(A)-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands. Ann. Med. 29, 275–282 (1997).
  CAS PubMed Google Scholar
• Dubnick, B. et al. The separation of 3_H_-benzodiazepine binding sites in brain and of benzodiazepine pharmacological properties. Pharmacol. Biochem. Behav. 18, 311–318 (1983).
  CAS PubMed Google Scholar
• Richter, P. H. & Scheefeldt, U. [Synthesis and biological activity of 5-phenyl-1,3,4-benzotriazepines. 25. Synthesis of (1,2,4)triazolo(4,3-a)(1,3,4)benzotriazepines and related tricyclics]. Pharmazie 46, 701–705 (in German) (1991).
  CAS PubMed Google Scholar
• McDonald, I. M. et al. Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK2 antagonists that display high selectivity over CCK1 receptors. J. Med. Chem. 49, 2253–2261 (2006).
  CAS PubMed Google Scholar
• Fernandez, P. et al. A novel indazolo-triazolo-benzotriazepine exerts anti-inflammatory effects by inhibition of cyclooxygenase-2 activity and nitric oxide synthase-2 expression. Naunyn Schmiedebergs Arch. Pharmacol. 368, 26–32 (2003).
  CAS PubMed Google Scholar
• Morgenstern, O. Chemistry and biological activity of 1,3,4-benzotriazepines, part 3. Pharmazie 55, 871–891 (2000).
  CAS PubMed Google Scholar
• Lange, B. et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 70, 192–199 (1987).
  CAS PubMed Google Scholar
• Matzuk, M. M. et al. Small-molecule inhibition of BRDT for male contraception. Cell 150, 673–684 (2012).
  CAS PubMed PubMed Central Google Scholar
• Kempen, H. Use of a thienotriazolodiazepine to increase apolipoprotein A-I levels. WO 1997/09048 A1 (1997).
• Kempen, H. J. et al. Stimulation of hepatic apolipoprotein A-I production by novel thieno-triazolodiazepines. Lipid Insights 6, 47–54 (2013).
  PubMed PubMed Central Google Scholar
• Mirguet, O. et al. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J. Med. Chem. 56, 7501–7515 (2013).
  CAS PubMed Google Scholar
• Mirguet, O. et al. From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151. Bioorg. Med. Chem. Lett. 22, 2963–2967 (2012).
  CAS PubMed Google Scholar
• Bradner, J. E. & Qi, J. Compositions and methods for treating neoplasia, inflammatory disease and other disorders. WO 2011/143669 A2 (2011).
• Bradner, J. E. & Brown, J. Compositions and methods for modulating metabolism. WO 2011/143651 A1 (2011).
• Bradner, J. E., Zuber, J., Shi, J. & Vakoc, C. R. Compositions and methods for treating leukemia. WO 2011/143660 A2 (2011).
• Bradner, J. E., Matzuk, M. & Qi, J. Male contraceptive compositions and methods of use. WO 2011/143657 A1 (2011).
• Albrecht, B. K. et al. Preparation of triazole derivatives as bromodomain inhibitors for treatment of cancers and disorders. WO 2012/075456 A1 (2012).
• Schmees, N. et al. 6_H_-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines as anticancer agents. WO 2013/030150 A1 (2013).
• Gosmini, R. L. M. & Mirguet, O. Benzodiazepine bromodomain inhibitor. WO 2011/054553 A1 (2011).
• Crowe, M. et al. Condensed azepine derivatives as bromodomain inhibitors. WO 2011/054844 A1 (2011).
• Bailey, J., Gosmini, R. L. M., Mirguet, O. & Witherington, J. Benzodiazepine bromodomain inhibitor. WO 2011/054845 A1 (2011).
• Bailey, J. M. Benzotriazolodiazepine compounds inhibitors of bromodomains. WO 2011/161031 A1 (2011).
• Albrecht, B. K. et al. Bromodomain inhibitors and uses thereof. WO 2012/151512 A2 (2012).
• Albrecht, B. K. et al. Bromodomain inhibitors and uses thereof. WO 2012/075383 A2 (2012).
• Chung, C.-W. & Nicodeme, E. Bromodomain inhibitors for treating autoimmune and inflammatory diseases. WO 2011/054843 A1 (2011).
• Seal, J. et al. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). Bioorg. Med. Chem. Lett. 22, 2968–2972 (2012).
  CAS PubMed Google Scholar
• Demont, E. H., Jones, K. L. & Watson, R. J. 4-(8-methoxy-1-((1-methoxypropan-2-Yl)-2-(tetrahydro-2h-pyran-4-Yl)-1_H_-imidazo[4,5-C]quinolin-7-Yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor. WO 2013/024104 A1 (2013).
• Bouillot, A. M. J. et al. Imidazo [4, 5-c] quinoline derivates as bromodomain inhibitors. WO 2011/054846 A1 (2011).
• Demont, E. H. & Gosmini, R. L. M. Thetrahydroquinolines derivatives as bromodomain inhibitors. WO 2011/054848 A1 (2011).
• Bamborough, P. & Chung, C. W. Novel process. WO 2011/054851 A1 (2011).
• Picaud, S. et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET bromodomains. Cancer Res. 73, 3336–3346 (2013).
  CAS PubMed PubMed Central Google Scholar
• Fish, P. V. et al. Novel heterocyclic compounds as bromodomain inhibitors. WO 2013/027168 A1 (2013).
• Hansen, H. Compounds for the prevention and treatment of cardiovascular diseases. WO 2008/092231 A1 (2008).
• Hansen, H. C. et al. Methods of preparing quinazolinone derivatives. WO 2009/158404 A1 (2009).
• Hansen, H. C. et al. Novel anti-inflammatory agents. WO 2010/123975 A1 (2010).
• Bailey, D. et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J. Am. Coll. Cardiol. 55, 2580–2589 (2010).
  CAS PubMed Google Scholar
• Nicholls, S. J. et al. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc. Drugs Ther. 26, 181–187 (2012).
  CAS PubMed Google Scholar
• Joy, T. R. Novel HDL-based therapeutic agents. Pharmacol. Ther. 135, 18–30 (2012).
  CAS PubMed Google Scholar
• McLure, K. G. & Young, P. R. Preparation of substituted 2-phenyl-3_H_-quinazolin-4-ones and analogs as inhibitors of BET for treating cancer. WO 2013/156869 A1 (2013).
• Picaud, S. et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc. Natl Acad. Sci. USA 110, 19754–19759 (2013).
  CAS PubMed PubMed Central Google Scholar
• McLure, K. G. et al. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS ONE 8, e83190 (2013).
  PubMed PubMed Central Google Scholar
• Martin, M. P., Olesen, S. H., Georg, G. I. & Schonbrunn, E. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem. Biol. 8, 2360–2365 (2013).
  CAS PubMed Google Scholar
• Dittmann, A. et al. The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains. ACS Chem. Biol. 9, 495–502 (2014).
  CAS PubMed Google Scholar
• Ember, S. W. et al. The acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem. Biol. http://dx.doi.org/10.1021/cb500072z (2014).
• Gaulton, A. et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100–D1107 (2012).
  CAS PubMed Google Scholar
• Albrecht, B. K., Harmange, J. C., Cote, A. & Taylor, A. M. Bromodomain inhibitors for cancer therapy. WO 2012/174487 A2 (2012).
• Wang, L. et al. Bromodomain inhibitors. WO 2013/097601 A1 (2013).
• Arnold, L. D., Foreman, K. W. & Werner, D. S. Bivalent bromodomain ligands and methods of using same. WO 2013/033268 A2 (2013).
• French, C. A. et al. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 63, 304–307 (2003).
  CAS PubMed Google Scholar
• French, C. A. Demystified molecular pathology of NUT midline carcinomas. J. Clin. Pathol. 63, 492–496 (2010).
  PubMed Google Scholar
• French, C. A. Pathogenesis of NUT midline carcinoma. Annu. Rev. Pathol. 7, 247–265 (2012).
  CAS PubMed Google Scholar
• Reynoird, N. et al. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 29, 2943–2952 (2010).
  CAS PubMed PubMed Central Google Scholar
• Schwartz, B. E. et al. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res. 71, 2686–2696 (2011).
  CAS PubMed PubMed Central Google Scholar
• Katsumoto, T., Yoshida, N. & Kitabayashi, I. Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis. Cancer Sci. 99, 1523–1527 (2008).
  CAS PubMed Google Scholar
• Ohnishi, H. et al. A complex t(1;22;11)(q44;q13;q23) translocation causing MLL-p300 fusion gene in therapy-related acute myeloid leukemia. Eur. J. Haematol. 81, 475–480 (2008).
  CAS PubMed Google Scholar
• Camos, M. et al. Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res. 66, 6947–6954 (2006).
  CAS PubMed Google Scholar
• Zhang, Y. et al. Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16). Genes Chromosomes Cancer 41, 257–265 (2004).
  CAS PubMed Google Scholar
• Iyer, N. G., Ozdag, H. & Caldas, C. p300/CBP and cancer. Oncogene 23, 4225–4231 (2004).
  CAS PubMed Google Scholar
• Pasqualucci, L. et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471, 189–195 (2011).
  CAS PubMed PubMed Central Google Scholar
• Nebral, K. et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 23, 134–143 (2009).
  CAS PubMed Google Scholar
• Jang, M. K. et al. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 19, 523–534 (2005).
  CAS PubMed Google Scholar
• Gaucher, J. et al. Bromodomain-dependent stage-specific male genome programming by Brdt. EMBO J. 31, 3809–3820 (2012).
  CAS PubMed PubMed Central Google Scholar
• Zhang, W. et al. Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J. Biol. Chem. 287, 43137–43155 (2012).
  CAS PubMed PubMed Central Google Scholar
• Chaidos, A. et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood 123, 697–705 (2014).
  CAS PubMed Google Scholar
• Henssen, A. et al. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget 4, 2080–2095 (2013).
  PubMed PubMed Central Google Scholar
• Mertz, J. A. et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl Acad. Sci. USA 108, 16669–16674 (2011).
  CAS PubMed PubMed Central Google Scholar
• Herrmann, H. et al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget 3, 1588–1599 (2012).
  PubMed PubMed Central Google Scholar
• Fiskus, W. et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myeloid leukemia (AML) cells. Mol. Cancer Ther. http://dx.doi.org/10.1158/1535-7163.MCT-13-0770 (2014).
• Ott, C. J. et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 120, 2843–2852 (2012).
  CAS PubMed PubMed Central Google Scholar
• Da Costa, D. et al. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J. 3, e126 (2013).
  CAS PubMed PubMed Central Google Scholar
• Roderick, J. E. et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 123, 1040–1050 (2014).
  CAS PubMed PubMed Central Google Scholar
• Cheng, Z. et al. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin. Cancer Res. 19, 1748–1759 (2013).
  CAS PubMed PubMed Central Google Scholar
• Segura, M. F. et al. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res. 73, 6264–6276 (2013).
  CAS PubMed PubMed Central Google Scholar
• Wyce, A. et al. Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget 4, 2419–2429 (2013).
  PubMed PubMed Central Google Scholar
• Puissant, A. et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 3, 308–323 (2013).
  CAS PubMed PubMed Central Google Scholar
• Wyce, A. et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS ONE 8, e72967 (2013).
  CAS PubMed PubMed Central Google Scholar
• Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320–334 (2013).
  CAS PubMed PubMed Central Google Scholar
• Kim, T. K. & Maniatis, T. The mechanism of transcriptional synergy of an in vitro assembled interferon-β enhanceosome. Mol. Cell 1, 119–129 (1997).
  CAS PubMed Google Scholar
• Spilianakis, C. G., Lalioti, M. D., Town, T., Lee, G. R. & Flavell, R. A. Interchromosomal associations between alternatively expressed loci. Nature 435, 637–645 (2005).
  CAS PubMed Google Scholar
• Emadali, A. et al. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls rituximab response and tumour growth in aggressive lymphoid cancers. EMBO Mol. Med. 5, 1180–1195 (2013).
  CAS PubMed PubMed Central Google Scholar
• Pastori, C. et al. BET bromodomain proteins are required for glioblastoma cell proliferation. Epigenetics 9, 611–620 (2014).
  CAS PubMed PubMed Central Google Scholar
• Stewart, H. J., Horne, G. A., Bastow, S. & Chevassut, T. J. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1. Cancer Med. 2, 826–835 (2013).
  CAS PubMed PubMed Central Google Scholar
• Liu, S. et al. Targeting STAT5 in hematological malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Mol. Cancer Ther. http://dx.doi.org/10.1158/1535-7163.MCT-13-0341 (2014).
• Wyspianska, B. S. et al. BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms. Leukemia 28, 88–97 (2014).
  CAS PubMed Google Scholar
• Khochbin, S. When are the BET factors the most sensitive to bromodomain inhibitors? Transcription 4, 54–57 (2013).
  PubMed PubMed Central Google Scholar
• Chapuy, B. et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24, 777–790 (2013).
  CAS PubMed PubMed Central Google Scholar
• Tolani, B., Gopalakrishnan, R., Punj, V., Matta, H. & Chaudhary, P. M. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene http://dx.doi.org/10.1038/onc.2013.242 (2013).
• Pasparakis, M. Regulation of tissue homeostasis by NF-κB signalling: implications for inflammatory diseases. Nature Rev. Immunol. 9, 778–788 (2009).
  CAS Google Scholar
• Huang, B., Yang, X. D., Zhou, M. M., Ozato, K. & Chen, L. F. Brd4 coactivates transcriptional activation of NF-κB via specific binding to acetylated RelA. Mol. Cell. Biol. 29, 1375–1387 (2009).
  CAS PubMed Google Scholar
• Hargreaves, D. C., Horng, T. & Medzhitov, R. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 138, 129–145 (2009).
  CAS PubMed PubMed Central Google Scholar
• Zou, Z. et al. Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA. Oncogene http://dx.doi.org/10.1038/onc.2013.179 (2013).
• Mele, D. A. et al. BET bromodomain inhibition suppresses TH17-mediated pathology. J. Exp. Med. 210, 2181–2190 (2013).
  CAS PubMed PubMed Central Google Scholar
• Bandukwala, H. S. et al. Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. Proc. Natl Acad. Sci. USA 109, 14532–14537 (2012).
  CAS PubMed PubMed Central Google Scholar
• Mahdi, H. et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated α-enolase in the etiology of rheumatoid arthritis. Nature Genet. 41, 1319–1324 (2009).
  CAS PubMed Google Scholar
• Wang, F. et al. Brd2 disruption in mice causes severe obesity without type 2 diabetes. Biochem. J. 425, 71–83 (2010).
  CAS Google Scholar
• Belkina, A. C., Nikolajczyk, B. S. & Denis, G. V. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J. Immunol. 190, 3670–3678 (2013).
  CAS PubMed Google Scholar
• Wienerroither, S. et al. Regulation of NO synthesis, local inflammation, and innate immunity to pathogens by BET family Proteins. Mol. Cell. Biol. 34, 415–427 (2014).
  PubMed Google Scholar
• Anand, P. et al. BET bromodomains mediate transcriptional pause release in heart failure. Cell 154, 569–582 (2013).
  CAS PubMed PubMed Central Google Scholar
• Cullen, S. J., Ponnappan, S. & Ponnappan, U. Catalytic activity of the proteasome fine-tunes Brg1-mediated chromatin remodeling to regulate the expression of inflammatory genes. Mol. Immunol. 47, 600–605 (2009).
  CAS PubMed PubMed Central Google Scholar
• Roscioli, T. et al. Mutations in the gene encoding the PML nuclear body protein Sp110 are associated with immunodeficiency and hepatic veno-occlusive disease. Nature Genet. 38, 620–622 (2006).
  CAS PubMed Google Scholar
• Li, Z., Guo, J., Wu, Y. & Zhou, Q. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res. 41, 277–287 (2013).
  CAS PubMed Google Scholar
• Bisgrove, D. A., Mahmoudi, T., Henklein, P. & Verdin, E. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc. Natl Acad. Sci. USA 104, 13690–13695 (2007).
  CAS PubMed PubMed Central Google Scholar
• Boehm, D. et al. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 12, 452–462 (2013).
  CAS PubMed PubMed Central Google Scholar
• Kundu, M., Guermah, M., Roeder, R. G., Amini, S. & Khalili, K. Interaction between cell cycle regulator, E2F-1, and NF-κB mediates repression of HIV-1 gene transcription. J. Biol. Chem. 272, 29468–29474 (1997).
  CAS PubMed Google Scholar
• Richman, D. D. et al. The challenge of finding a cure for HIV infection. Science 323, 1304–1307 (2009).
  CAS PubMed Google Scholar
• Karn, J. The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Curr. Opin. HIV AIDS 6, 4–11 (2011).
  PubMed PubMed Central Google Scholar
• Wang, X. et al. Bromodomain protein Brd4 plays a key role in Merkel cell polyomavirus DNA replication. PLoS Pathog. 8, e1003021 (2012).
  CAS PubMed PubMed Central Google Scholar
• Wang, X., Helfer, C. M., Pancholi, N., Bradner, J. E. & You, J. Recruitment of Brd4 to the human papillomavirus type 16 DNA replication complex is essential for replication of viral DNA. J. Virol. 87, 3871–3884 (2013).
  CAS PubMed PubMed Central Google Scholar
• Yan, J., Li, Q., Lievens, S., Tavernier, J. & You, J. Abrogation of the Brd4-positive transcription elongation factor B complex by papillomavirus E2 protein contributes to viral oncogene repression. J. Virol. 84, 76–87 (2010).
  CAS PubMed Google Scholar
• Sharma, A. et al. BET proteins promote efficient murine leukemia virus integration at transcription start sites. Proc. Natl Acad. Sci. USA 110, 12036–12041 (2013).
  CAS PubMed PubMed Central Google Scholar
• Gupta, S. S. et al. Bromo- and extraterminal domain chromatin regulators serve as cofactors for murine leukemia virus integration. J. Virol. 87, 12721–12736 (2013).
  CAS PubMed PubMed Central Google Scholar
• Gamsjaeger, R. et al. Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3. Mol. Cell. Biol. 31, 2632–2640 (2011).
  CAS PubMed PubMed Central Google Scholar
• Lamonica, J. M. et al. Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. Proc. Natl Acad. Sci. USA 108, E159–E168 (2011).
  PubMed PubMed Central Google Scholar
• Tsume, M. et al. Brd2 is required for cell cycle exit and neuronal differentiation through the E2F1 pathway in mouse neuroepithelial cells. Biochem. Biophys. Res. Commun. 425, 762–768 (2012).
  CAS PubMed Google Scholar
• Berkovits, B. D. & Wolgemuth, D. J. The first bromodomain of the testis-specific double bromodomain protein Brdt is required for chromocenter organization that is modulated by genetic background. Dev. Biol. 360, 358–368 (2011).
  CAS PubMed PubMed Central Google Scholar
• Liu, L., Zhen, X. T., Denton, E., Marsden, B. D. & Schapira, M. ChromoHub: a data hub for navigators of chromatin-mediated signalling. Bioinformatics 28, 2205–2206 (2012).
  CAS PubMed PubMed Central Google Scholar